tbuckley/cabot-search huggingface dataset:
560P A next-generation sequencing analysis indicates genomic alterations in pathological morphologies: A genomic case report of pulmonary carcinosarcoma harbouring EGFR mutation
Authors: G. Koba, H. Kimura, Y. Amino, N. Terada, H. Matsuoka, S. Nishikawa, T. Yoneda, Y. Tambo, T. Sone, K. Kasahara
Journal: Annals of Oncology (2016)
Are There Racial and Socioeconomic Disparities in School Peanut-Free Policies?
Authors: Lisa M. Bartnikas, Michelle F. Huffaker, William J. Sheehan, Watcharoot Kanchongkittiphon, Carter R. Petty, Robert Leibowitz, Marissa Hauptman, Jonathan M. Gaffin, Michael C. Young, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2017)
Preclinical Efficacy Testing of Baxter's Recombinant FVIIa
Authors: Alexandra Schiviz, John-Philip Lawo, Marlene Resch, Peter Leidenmuehler, Bettina Bischetsrieder, Hartmut J. Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch
Journal: Blood (2010)
412P Effects of statins on melanoma
Authors: K.B. Tran, S. Kolekar, S.M.F. Jamieson, F.W. Hunter, A. Jabed, D. Li, W.R. Wilson, B.C. Baguley, J.H. Shih, C.M. Buchanan, P.R. Shepherd
Journal: Annals of Oncology (2016)
Fatigue in psoriasis: a controlled study
Authors: I.M. Skoie, I. Dalen, T. Ternowitz, G. Jonsson, I. Kvivik, K. Norheim, R. Omdal
Journal: British Journal of Dermatology (2017)

Fatigue is associated with various chronic inflammatory diseases, but few studies have focused on its occurrence in psoriasis. To describe fatigue prevalence and degree among patients with chronic plaque psoriasis vs. age‐ and sex‐matched healthy subjects, and to examine how fatigue is influenced by essential clinical and demographic factors. In 84 patients and 84 healthy subjects, fatigue severity was assessed using three different generic fatigue instruments: the fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS) and the Short Form 36 (SF‐36) Vitality scale. Cut‐off scores for clinically important fatigue were defined as ≥ 4 for FSS, ≥ 50 for fVAS and ≤ 35 for the SF‐36 Vitality scale. Disease activity was evaluated using the Psoriasis Area and Severity Index (PASI), and the impact on quality of life with the Dermatology Life Quality Index (DLQI). Patients and healthy control subjects, respectively, showed median fVAS scores of 51 [interquartile range (IQR) 21–67] and 11 (IQR 3–20); FSS scores of 4 (IQR 2·5–5·3) and 1·6 (IQR 1·1–2·2); and SF‐36 Vitality scores of 43 (IQR 25–85) and 73 (IQR 65–85). The rates of clinically important fatigue among patients vs. healthy controls, respectively, were 51% vs. 4% (fVAS); 52% vs. 4% (FSS); and 42% vs. 2% (SF‐36 Vitality) (P < 0·001 for all differences). Fatigue was associated with DLQI scores, but not PASI scores, in univariate analysis but not in multivariate analysis. Nearly 50% of patients with psoriasis suffered from substantial fatigue. Fatigue severity was associated with smoking, pain and depression, but not with psoriasis severity.
MMSET Regulates IRF4, a Transcription Factor Critical for the Survival of T(4;14) Myeloma Myeloma Cells, and Its Silence Potentiates the Effect of Antimyeloma Agents
Authors: Zhigang Xie, Chonglei Bi, Jing Yuan Chooi, Zit Liang Chan, Nurulhuda Mustafa, Wee Joo Chng
Journal: Blood (2014)
Diversity of HLA Class I and Class II Restricted Minor Histocompatibility Antigens in Graft-Versus-Leukemia Reactivity.
Authors: Marieke Griffioen, M. Willy Honders, Anita N. Stumpf, Edith D. van der Meijden, Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Elisabeth G.A. Lurvink, Roel Willemze, J.H. Frederik Falkenburg
Journal: Blood (2009)
palliative care Evaluation of effects of early palliative care on quality of life of advanced cancer patients. A multicenter controlled randomised clinical trial
Authors: V. Franciosi, G. Caruso, G. Maglietta, Cgli De Esposti, L. Cavanna, R. Bertè, G. Bacchini, L. Bocchi, E. Piva, M. Monfredo, V. Scafuri, P. Di Cesare, B. Melotti, M. Sequino, A. Rimanti, C. Binovi, F. Ghisoni, C. Caminiti
Journal: Annals of Oncology (2016)
P14.07 Posterior reversible encephalopathy syndrome and new hormone therapy for prostate cancer
Authors: M. Sequeira, F. Carneiro
Journal: Neuro-Oncology (2016)

BACKGROUND: Oxaliplatin (OXA) is the first-line chemotherapy agent in the treatment of colorectal cancer (CRC).OXA-induced neuropathy is the most frequent long-term side-effect.Retreatment with OXA is frequently considered in patients as salvage treatment.MATERIAL: Patients receiving OXA-based chemotherapy regimen twice in our institution between 2009 and 2015 were reviewed.The aim of this study was to investigate whether retreatment with OXA increases the risk of developing or worsening previous OXA-induced peripheral neuropathy.The severity of neuropathy was measured by National Cancer Institute (NCI), Total Neuropathy Score (TNS) and nerve conduction studies (NCS).RESULTS: Sixty CRC patients were included in the analysis.Median age at OXA-based treatment was 61 years.29, 27, 2 and 2 patients received FOLFOX-4, FOLFOX-6, CAPOX and other OXA-based regimen, respectively, the first time, and 0, 53, 3 and 4 patients in the retreatment, respectively.After the first-line OXA-based chemotherapy, 56.8% of patients developed peripheral neuropathy, after a median of 11 [1-14] cycles.Severity of neuropathy was grade 1 (24.1%),grade 2 (29.3%), and grade 3 (3.4%).Mean time to retreatment with OXA was 29.46 ± 11.9 months.Frequencies of neuropathy before retreatment were as follows: 66.7% grade 0, 25% grade 1 and 8.3% grade 2. After retreatment, severities of neuropathy were 35.1% grade 1, 19.3% grade 2. No patient developed grade 3. 45.6% of patients did not develop neuropathy (grade 0).Peripheral neurotoxicity was the reason for stopping treatment prematurely after first-line and retreatment in 15% and 5 % of patients, respectively.Worsening of previous NCI score was observed in 23% of patients.The great majority of patients (77%) remained within the same NCI score than before retreatment.Median cycles in the retreatment were 7.5 [1-14].Among those patients that did not develop neuropathy according NCI (grade 0) after first treatment with OXA (n=26), only 4 (15%) and 2 (7%) patients developed grade 1 and 2, respectively, after a median of 7 [1-14] cycles.Among those patients who initially developed grade 2 and 3 neuropathy and had TNS assessment (n=19), no differences in median TNSc just before and after finishing retreatment with OXA were identified (6 [4-10] vs 6.5 [4-12], p=0.408).CONCLUSION: Retreatment with oxaliplatin in CRC patients is a feasible option even in patients who developed moderate or severe OXAinduced neuropathy previously.Lack of worsening of previous neurotoxicity is observed in the great majority of patients.Neurological monitoring of patients candidates to retreatment with OXA should be recommended to ensure the safety. P14.
A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial
Authors: D.J. Jonker, L. Nott, T. Yoshino, S. Gill, J. Shapiro, A. Ohtsu, J. Zalcberg, M.M. Vickers, A. Wei, Y. Gao, N. Tebbutt, B. Markman, T. Esaki, S. Koski, M. Hitron, N.M. Magoski, J. Simes, C. Li, D. Tu, C.J. O'Callaghan
Journal: Annals of Oncology (2016)
Evaluation of pro-inflammatory cytokines and anxiety symptoms in early-stage breast cancer (ESBC) patients: A prospective, longitudinal study.
Authors: Terence NG, Shi Yin Yap, Maung Shwe, Yan Xiang Gan, Yin Ting Cheung, Gilbert Fan, Wei Sean Yong, Preetha Madhukumar, Kiley Wei-Jen Loh, Si-Lin Koo, Amit Jain, Guek Eng Lee, Mabel Wong, Rebecca Alexandra Dent, Yoon Sim Yap, Raymond C.H. Ng, Han Kiat Ho, Alexandre Chan
Journal: Journal of Clinical Oncology (2015)

e20742 Background: It is hypothesized that pro-inflammatory cytokines dysregulation gives rise to anxiety symptoms in cancer patients. However, the specific cytokines associated with this condition remains unknown. This study aims to identify pro-inflammatory biomarkers that are associated with anxiety symptoms in ESBC patients. Methods: This was a multi-centered, prospective, longitudinal study conducted between 2011 and 2014. Chemotherapy-receiving ESBC patients were recruited. Anxiety symptoms, cancer-related fatigue (CRF) and health-related QOL were measured using Beck Anxiety Inventory (BAI), Brief Fatigue Inventory (BFI), and EORTC-QLQ-C30, respectively. Pro-inflammatory plasma cytokines concentrations (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-γ, GM-CSF) were measured using multiplex immunoassay at three time points: prior to chemotherapy (T1), at midpoint (T2), and end of chemotherapy (T3). Associations were evaluated using the generalized estimating equation model, adjusting for clinically important covariates. Results: 101 patients were recruited (mean age: 50.4 ± 8.5 years; 82% Chinese). More patients experienced moderate to severe degree of anxiety at T3 (18.2%), comparing to T1 (9.3%) and T2 (12.1%). At T3, most patients experienced anxiety symptoms from the autonomic (p < 0.001) and neurophysiological subdomains (p < 0.001). Anxiety symptoms were positively associated with CRF (β = 0.134, p < 0.001), and global QOL was inversely associated with anxiety levels (β = -0.009, p < 0.001). Dysregulation of cytokines was observed with the onset of anxiety symptoms over time; higher concentrations of IL-10 (β = 0.001, p = 0.022) and lower concentrations of IL-4 (β = -0.038, p = 0.043) were associated with higher levels of anxiety. No significant associations were observed with the remaining cytokines. Conclusions: While elevated concentrations of IL-10 were observed in ESBC patients with anxiety symptoms, the converse was observed with IL-4. This study provides evidence suggesting that inflammation plays a role with the onset of anxiety symptoms in cancer patients.
Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients
Authors: Christopher Arthur, Charmaine Wong, Brandon Aubrey, Eunice Liu, William Stevenson, Gary Soo, Luke Coyle, Keith Fay, Matthew Greenwood, Naomi Mackinlay, Christopher M Ward
Journal: Blood (2012)
Effect of pericytes on epithelial-to-mesenchymal transition in melanoma.
Authors: Jose Humberto Trevino-Villarreal, Rosalinda Sepulveda, Douglas A. Cotanche, Rick A. Rogers
Journal: Journal of Clinical Oncology (2012)

84 Background: Melanoma-associated stroma cells play an important role in supporting cancer cell proliferation, invasion, and dissemination. Increased invasiveness has been observed in cancer cells undergoing epithelial-to-mesenchymal transition (EMT); however, it is unknown whether EMT is facilitated by stroma cells. We showed that pericytes constitute a predominant stroma subpopulation that promotes melanoma growth by interacting with cancer cells. This study investigates the mechanism by which pericytes facilitate melanoma development. Methods: GFP + pericytes isolated from tumors and adipose tissue were co-cultured in vitro with B16 melanoma cells at a 3:1 ratio. After 4 days, proliferation of B16 cells and pericytes was assessed. Also, co-cultures were labeled for several markers and analyzed by flow cytometry (FC). Tumorigenicity was investigated by isolating B16 cells from co-cultures by FACS sorting and then injected into SCID mice to measure tumor growth. Results: B16 cells induced pericyte differentiation into FAP + myofibroblasts. However, no change in the pericyte proliferation rate was observed. B16 cells co-cultured with pericytes, and later separated by FACS sorting, displayed faster proliferation rates in vitro, and induced increased tumor growth rates when injected into SCID mice, compared with naive B16 cells. Pericytes increased B16 cell proliferation rate and induced a change in cell morphology, from cobblestone to fibroblast-like colonies. Interaction between B16 cells and pericytes in co-culture increased pericyte production of TGF-β and increased the expression of the stem cell markers SSEA-1, OCT3/4 and CD271 in B16 cells. In addition, cadherin switching, demonstrated by loss of E-cadherin expression and an up-regulation of the mesenchymal markers N-cadherin and vimentin was observed in B16 cells. Conclusions: Pericyte production of TGF-β promotes B16 cell development of EMT, as shown by loss of E-cadherin expression and up-regulation of the mesenchymal markers N-cadherin and vimentin, resulting in an increase in melanoma cell tumorigenicity. These results suggest that therapies targeting stromal pericytes may be a promising approach for melanoma treatment.
Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
Authors: R. Finn, S.L. Chan, A.X. Zhu, J. Knox, A.-L. Cheng, A. Siegel, O. Bautista, P.A. Watson, M. Kudo
Journal: Annals of Oncology (2016)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with Treatment Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia (tMDS/AML)
Authors: Rachel Kobos, Peter G Steinherz, Nancy A Kernan, Susan E Prockop, Andromachi Scaradavou, Trudy N Small, Neerav Shukla, Ramzi Khalaf, Richard J. O'Reilly, Farid Boulad
Journal: Blood (2010)
P09.14 Clonal and subclonal evolution of 1p/19q co-deleted oligodendrogliomas
Authors: A. Alentorn, M. Daniau, L. Royer-Perron, K. Labreche, A. Duran-Pena, Y. Marie, K. Hoang-Xuan, M. Sanson, J. Delattre, A. Idbaih
Journal: Neuro-Oncology (2016)
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations
Authors: Maria Chiara Fontana, Giovanni Marconi, Jelena D. Milosevic Feenstra, Cristina Papayannidis, Marco Manfrini, Viviana Guadagnuolo, Giorgia Simonetti, Antonella Padella, Anna Ferrari, Eugenia Franchini, Andrea Ghelli Luserna di Rorà, Emanuela Ottaviani, Rossella De Tommaso, Samantha Bruno, Simona Soverini, Nicoletta Testoni, Stefania Paolini, Chiara Sartor, Sarah Parisi, Elena Tenti, Robert Kralovics, Giovanni Martinelli
Journal: Blood (2016)
Small cell neuroendocrine carcinoma of uterine cervix: The Scottish experience
Authors: M. Siva, R. Mahmood, S. Kakumanu, A. Sadozye, N. Reed
Journal: Journal of Clinical Oncology (2006)

15026 Background: Small cell neuroendocrine carcinoma (SCC) of uterine cervix is a rare sub-type of cervical cancer. We report the results of a retrospective analysis of data from 2 Scottish centres of cases of SCC of cervix. The aim is to examine therapeutic interventions, relapse patterns and survival. Methods: Eligible cases were patients (pts) with cervical SCC presented for management discussion between 1995 and 2005 in the 2 scottish centres. Pathology was reviewed centrally by the network pathologists. We reviewed pts case records for staging information, therapeutic interventions, median time to relapse, salvage therapy and responses and overall survival. Results: A total of 21 pts were eligible for the analysis (Glasgow-13 and Aberdeen-8). The median age of the pts was 33 (Range 22–74). Nine pts were FIGO stage 1B, 3 were 2A and 4 were 2B, 3 were 3B and 2 with metastatic disease. Surgery was done in 13 pts [11-radical hysterectomy/pelvic lymphadenectomy, 1-radical hyseterctomy and 1-total abdominal hysterectomy]. Chemotherapy was given to 16 pts [Neo-adjuvant-6, Adjuvant-9, Concurrent-3]. Fourteen pts received combination chemotherapy containing Platinum and Etoposide [EP-2, CE-8, ICE-1 and ACE-3]. One received non-platinum combination. Fourteen pts received radiotherapy [10-Pelvic radiotherapy and brachytherapy, 3-Pelvic only, 1-Brachytherapy only, 2-PCI]. Two pts died of progressive disease shortly after diagnosis without any specific anti-cancer treatment, two pts were disease free after a follow up of 40 and 53 months respectively and one was lost to follow up 7 yrs after diagnosis. Median relapse free survival (RFS) was 16 months. Two year RFS was 25%. The sites of relapse were as follows: Liver-4, Chest-4, Para-aortic-4, Brain-3, Neck-3, Local-2, Abdomen-1. Twelve pts received salvage therapy after relapse [5-responded, 2-not assessed and 5-progressed]. Seven pts were alive after a median follow up of 40 months [Range 17–90]. Median survival was 28 months and the three year overall survival was 45%. Conclusions: We have shown here that with combination treatment SCC can be effectively managed with occasional durable remissions. The overall survival at 3 years was 45%. We believe this was the result of aggressive combination therapy of surgery, chemo and radiotherapy. No significant financial relationships to disclose.
Rocaglamide Selectively Eradicates Human Leukemia Stem Cells and Synergizes with Multiple Agents to Target AML Cells
Authors: Kevin P Callahan, Cheryl Corbett, Steven Jacob, Mohammad Minhajuddin, Eleni D Lagadinou, Randall M Rossi, Valerie Gross, Marlene Balys, Fred Hagen, Alison J Frontier, Craig T. Jordan
Journal: Blood (2012)
Magnetic resonance imaging evaluation of radiation: Cranial radiation therapy-induced diffuse white matter injury
Authors: T. Z. Mohran, M. M. Omar, M. A. Hameed, M. S. Elnaggar
Journal: Journal of Clinical Oncology (2009)

e13033 Background: To study the value of MRI in detection and grading of diffuse white matter injury induced by cranial radiation therapy for brain tumors and to evaluate the influence of various risk factors for its development. Methods: This study included 60 patients who had primary brain tumors and received external beam conventionally fractionated radiotherapy. Twenty-three out of 60 patients received chemotherapy after radiotherapy. Post radiotherapy follow-up MRI examination was performed for all patients at 6 weeks, 3, 6, 9, 12 months, and at more than 1 year from completion of radiotherapy. MR imaging was performed with T2-weighted turbo spin echo, fast fluid-attenuated inversion- recovery (FLAIR), T1-weighted spin-echo, and T1-weighted post-contrast spin-echo sequences. Results: Twenty-one of 60 patients (35%) developed diffuse white matter injury at a mean of 15.3 + 7.6 months from the completion of radiotherapy (range, 5–36 months). Radiation-related diffuse white matter changes were characterized as diffuse high signal intensity in the periventricular deep white matter on T2WI and FLAIR sequences. The MRI grading system of these periventricular hyperintensity (PVH) were as follow: 39 patients (65%) had no WMI (grade 0), four had grade 1 changes, three patients had grade 2 changes, nine patients had grade 3, and five patients had grade 4. They were symmetrical in 13 of 21 patients (61.9%), and asymmetrical in eight out of 21 patients (38.1%). The prevalence of diffuse matter injury found to be significantly related to the volume of irradiation (p = 0.02), fraction size (p = 0.008), and concomitant use of chemotherapy (p &gt; 0.02)Conclusions: Diffuse white matter injury is a known consequence of radiation therapy, and the capability of detecting and grading such damage is optimally provided by MRI. No significant financial relationships to disclose.
Effect of long term prophylaxis with attenuated androgen (AA-LTP) on the risk for cardiovascular and neoplastic diseases in a cohort of 289 patients with Hereditary Angioedema (HAE) due to C1 inhibitor deficiency.
Authors: Antonio Gidaro, Francesca Perego, Elena Colombo, Mauro Cancian, Andrea Zanichelli, Maddalena Alessandra Wu, Marco Cicardi
Journal: Journal of Allergy and Clinical Immunology (2017)
Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
Authors: F. Barlesi, E. Garon, D.-W. Kim, E. Felip, J.-Y. Han, J.-H. Kim, M.-J.A. Ahn, M.J. Fidler, M.A. Gubens, G. Castro,, V. Surmont, Q. Li, A.C. Deitz, G. Lubiniecki, R.S. Herbst
Journal: Annals of Oncology (2016)
Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
Authors: S. Lonardi, A.L. Cohn, T. Yoshino, R. Obermannova, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. Garcia-Alfonso, D.C. Portnoy, E. Van Cutsem, K. Yamazaki, P.R. Clingan, J. Polikoff, L. Gao, L. Yang, S. Chang, D. Ferry, F. Nasroulah, J. Tabernero
Journal: Annals of Oncology (2016)
The TCL1 Gene Is Involved, Other Than in Lymphoid Differentiation and Early Embryogenesis, Also in the Development of the Hair Follicle.
Authors: Gianluca Ragone, Antonella Bresin, Maria Cristina Picchio, Cristina Lazzeri, Cristina Cristofoletti, Sang-Moo Kang, Maria Grazia Narducci, Giandomenico Russo
Journal: Blood (2005)
Beyond mortality or being mortal? Challenges in understanding and improving life after ARDS
Authors: Catherine L Hough
Journal: Thorax (2017)

In 2009, the National Heart Lung and Blood Institute (NHLBI) of USA convened a workshop to discuss the state of clinical and translational science for acute respiratory distress syndrome (ARDS). The panel reviewed epidemiological studies and clinical trials suggesting marked declines in ARDS-related mortality, and discussed observational studies that described the enduring morbidities of ARDS survivorship. The report of this meeting described the challenges of clinical trials focused on mortality and charged clinical researchers to move ‘beyond mortality’ (as the report was entitled) by including functional, cost and quality of life outcomes in future research.1

Over the last decade, the charge of measuring these long-term outcomes has indeed been realised. Along with observational studies, large interventional trials have begun to include outcome assessment at 6 and 12 months after initial trial enrolment, including four large trials conducted by the NHLBI ARDS Clinical Trials Network. This work, led by Needham and Hopkins, collectively called the ARDSNet Long-Term Outcome Study (ALTOS), has led to the largest cohort of ARDS survivors described to date, confirming the findings of preceding single-centre cohorts2–4 by revealing an overwhelming degree of post intensive care unit (ICU) morbidity, with persisting impairments in physical, cognitive and mental health function, and health-related quality of life well below expected.5–7

Certainly, ancillary inclusion of long-term outcomes as secondary or exploratory end points provides valuable information. However, proving that specific interventions improve long-term outcomes as well as survival requires primary study end points beyond mortality, such as quality of life or health utilities. While such end points are increasingly common in other fields, there are no large ARDS clinical trials to date with primary outcomes focused on long-term survivorship end points such as quality of life. Since early mortality remains high in ARDS, 20% or more in most randomised trial populations, …